Clinical Trials Logo

Follicular Lymphoma Grade 3A clinical trials

View clinical trials related to Follicular Lymphoma Grade 3A.

Filter by:
  • None
  • Page 1

NCT ID: NCT05377307 Recruiting - Clinical trials for Diffuse Large B Cell Lymphoma

Long-term Follow-up Study of Lentiviral-based Gene-edited Immune Cell Therapy

Start date: December 29, 2022
Phase:
Study type: Observational

According to health authorities guidances (FDA 2006, EMA(European Medicines Agency) 2009) for gene therapy clinical trials, observing subjects for delayed adverse events for 15 years is recommended. This purpose of this long-term follow-up study is to evaluate the safety and efficacy in patients who have ever received lentiviral-based gene-edited immune cells which are manufactured by Pell Bio-Med Technology Co. Ltd.

NCT ID: NCT05326243 Recruiting - Clinical trials for Diffuse Large B Cell Lymphoma

Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma

Start date: May 31, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This is a multiple center, non-randomized, open-label, phase 1/2 study. The primary objective of Phase 1 is to evaluate the safety of PL001 and find the recommended Phase 2 dose (RP2D). The objective of Phase 2 is to evaluate the safety and efficacy of CD19 CAR-T(known as PL001).

NCT ID: NCT02710643 Completed - Clinical trials for Follicular Lymphoma, Grade 1

"MIRO" Molecularly Oriented Immuno-radio-therapy

FIL_MIRO
Start date: October 2014
Phase: Phase 2
Study type: Interventional

Phase II prospective multicenter study for stage I/II Follicular Lymphoma treated with involved-field radiotherapy (IFRT) at doses of 24 Gy) with or without Ofatumumab for 8 weekly doses on molecular basis. Patients with positive basal Bcl-2 will be followed every 3 months and with Bcl-2 detection every 6 months for 3 years. Patient with negative basal Bcl-2 will be followed every 3 months without further Bcl-2 detection. Ofatumumab treatment will be administered to: 1. Patients with positive basal PCR for Bcl-2-IgH rearrangement in BM and/or PB, resulting still positive after IFRT; 2. Patients with positive basal PCR for Bcl-2-IgH in